Pathway Diagnostics' technology detects the CXCR4 HIV co-receptor in patient samples that have as little as one percent CXCR4-tropic virus, enabling physicians to identify with a high degree of accuracy those patients with X4-tropic virus who are unlikely to benefit from, and should not receive, treatment with entry inhibitor
With several major phase II studies in progress or set to launch, hope for oral entry inhibitors
is at an all-time high.
Trimeris also has a second-generation entry inhibitor
in early clinical trials.
Our HCV entry program leverages our expertise in the discovery and development of HIV entry inhibitors
such as PRO 140, which is currently in phase 2 clinical trials.
Other investigators working on entry inhibitors
have made new and exciting observations that may provide a glimpse into the future of entry inhibitors
Our testing services are used in clinical programs of CCR5 entry inhibitor
drugs, for patient selection and monitoring utilizing our Co-Receptor Tropism Assay, and for optimization of patients' background treatment regimens utilizing our PhenoSense GT test.
Monogram's assays utilizing this technology include the PhenoSense(TM) Entry Assay that assesses resistance of HIV to all classes of entry inhibitor
drugs and the Co-Receptor Tropism Assay that identifies the ability of a patient's HIV to enter cells using specific co-receptors such as CCR5.
These forward-looking statements include references to the potential use for the Company's tests in early access programs as well as in commercial use of CCR5 entry inhibitor
drugs if approved by the FDA, and the potential impact of the Contingent Value Rights.
Lee Henderson, will discuss the company's Influenza drug, an active entry inhibitor
for all strains of Influenza and its drug development technologies.
In order to efficiently block intracellular fusion events, the next generation of HIV entry inhibitors
must be able to permeate the cell membrane," he added.
All the other products mentioned are called HIV entry inhibitors
and block HIV infection.
SAN FRANCISCO -- Efforts to develop entry inhibitors
, which constitute the first new class of anti-HIV drugs in years, have hit snags that could delay the entry of these novel agents into the pharmaceutical marketplace.